HIV coreceptor phenotyping in the clinical setting.


The introduction of CCR5 antagonists increases the options available for constructing antiretroviral regimens. However, this option is coupled with the caveat that patients should be tested for HIV coreceptor tropism prior to initiating CCR5 antagonist-based therapy. Failure to screen for CXCR4 usage increases the risk of using an ineffective drug, thus… (More)


Cite this paper

@article{Low2008HIVCP, title={HIV coreceptor phenotyping in the clinical setting.}, author={Andrew J. Low and Luke C. Swenson and P. Richard Harrigan}, journal={AIDS reviews}, year={2008}, volume={10 3}, pages={143-51} }